LIST OF FIGURES
• FIGURE 27
• FIGURE 28
INTERMEDIATE-ACTING DRUGS WILL CONTINUE TO DOMINATE THE HUMAN INSULIN BIOLOGICS MARKET TILL 2020.................................................................................... 69
NORTH AMERICA IS EXPECTED TO DOMINATE THE INTERMEDIATE-ACTING HUMAN INSULIN BIOLOGICS MARKET DURING THE STUDY PERIOD........................................................................... 71
• FIGURE 29 INSULIN ANALOGS & BIOSIMILAR DRUGS POISED TO GROW AT THE FASTEST RATE.................................. 75
• FIGURE 30
• FIGURE 31
• FIGURE 32
• FIGURE 33
LANTUS EXPECTED TO HOLD THE LARGEST SHARE OF INSULIN ANALOGS & BIOSIMILAR BRANDS MARKET TILL 2020.................................................................................................... 76
ASIA-PACIFIC POISED TO BE THE FASTEST-GROWING MARKET FOR NOVORAPID DURING THE FORECAST PERIOD.................................................................................................................................... 79
HUMULIN IS POISED TO BE THE FASTEST-GROWING HUMAN INSULIN BIOLOGICS BRANDS DURING 2015-2020............................................................................................................................ 82
INSULIN PENS TO DOMINATE THE HUMAN INSULIN DELIVERY DEVICES MARKET DURING THE FORECAST PERIOD( 2015 – 2020).............................................................................................................. 87
• FIGURE 34 APAC TO DOMINATE THE HUMAN INSULIN PEN NEEDLES MARKET BY 2020................................................ 91
• FIGURE 35 INDIA WILL HAVE THE HIGHEST DIABETES POPULATION BY 2030................................................................. 97
• FIGURE 36 MARKET TRENDS: NORTH AMERICAN HUMAN INSULIN MARKET( 2015-2020)........................................... 102
• FIGURE 37 MARKET TRENDS: EUROPEAN HUMAN INSULIN MARKET( 2015-2020)....................................................... 108
• FIGURE 38 ASIA-PACIFIC HUMAN INSULIN MARKET SNAPSHOT, 2015-2020................................................................ 117
• FIGURE 39
LEADING PLAYERS ADOPTED THE STRATEGY OF GEOGRAPHIC EXPANSIONS TO STRENG THEN THEIR MARKET POSITIONING DURING 2012 TO 2015......................................................................... 126
• FIGURE 40 GLOBAL HUMAN INSULIN MARKET SHARE, BY KEY PLAYER( 2014)............................................................ 127
• FIGURE 41 GLOBAL HUMAN INSULIN DRUGS MARKET RANKING, BY KEY PLAYER( 2014)........................................... 129
• FIGURE 42 GLOBAL HUMAN INSULIN DELIVERY DEVICES MARKET RANKING, BY KEY PLAYER( 2014)....................... 130
• FIGURE 43
CONTINUOUS GEOGRAPHIC EXPANSION IS STIMULATING MARKET COMPETITION FOR CAPACITY BUILDING AMONG KEY PLAYERS......................................................................................... 131
• FIGURE 44 GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS *( 2014)....................................................... 139
• FIGURE 45
• FIGURE 46
LEADING COMPANIES ARE FOCUSING ON CAPACITY BUILDING TO STRENGTHEN THEIR PRODUCT DEVELOPMENT & MANUFACTURING BASE....................................................................... 141
LEADING HUMAN INSULIN MANUFACTURERS ARE FOCUSING ON PRODUCT COMMERCIALIZATION TO STRENGTHEN THEIR MARKET POSITION............................................................. 142
• FIGURE 47 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT...................................................................................... 143
• FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT..................................................................... 145
sales @ marketsandmarkets. com www. marketsandmarkets. com
23